馃敩 #ESMO26 | La Dra. @rebecaLozMe, portavoz de @_SEOM, analiza DASL-HiCaP (LBA4), presentado en la Sesi贸n Presidencial del Congreso de @myESMO 2026.
馃К Darolutamida + radioterapia + privaci贸n androg茅nica mejora la supervivencia libre de met谩stasis en c谩ncer de pr贸stata: 95% vs. 88% a 4 a帽os.
48 views 路 0 likes 路 0 reposts 路 0 replies
Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgINTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgSource: SEOM 路 x.com